Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24412467 | 0.97 | HTT (0.48) | HTTMEN1THRBKMT2AMAPT | |
| SCHEMBL18902544 | 0.97 | HTT (0.48) | HTTMEN1THRBKMT2AMAPT | |
| SCHEMBL17137852 | 0.94 | HTT (0.52) | HTTMEN1THRBKMT2AMAPT | |
| SCHEMBL627684 | 0.94 | TSHR (0.43) | HTTMEN1THRBKMT2AMAPT | |
| SCHEMBL874663 | 0.94 | TSHR (0.43) | HTTMEN1THRBKMT2AMAPT | |
| SCHEMBL3966692 | 0.92 | HTT (0.56) | HTTMEN1THRBKMT2AMAPT | |
| SCHEMBL30143832 | 0.91 | THRB (0.42) | HTTMEN1THRBKMT2AMAPT | |
| SCHEMBL25864715 | 0.91 | THRB (0.42) | HTTMEN1THRBKMT2AMAPT | |
| SCHEMBL2551087 | 0.90 | TSHR (0.50) | HTTMEN1THRBKMT2AMAPT | |
| SCHEMBL2473861 | 0.90 | ALDH1A1 (0.50) | HTTMEN1THRBKMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331681-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2023-10-19 | — | — | US | disclosed |
| US-20180072711-A1 | INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS, INC. | 2018-03-15 | — | — | US | disclosed |
| US-20170327469-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2017-11-16 | — | — | US | disclosed |
| EP-1655291-B1 | COMPOUNDS HAVING THROMBOPOIETIN RECEPTOR AGONISM | SHIONOGI & CO (JP) | 2016-08-03 | — | — | EP | disclosed |
| US-20160214972-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2016-07-28 | — | — | US | disclosed |
| US-9056043-B2 | Dental compositions comprising ethylenically unsaturated addition-fragmentation agent | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2015-06-16 | — | — | US | disclosed |
| US-20090318513-A1 | COMPOUNDS EXHIBITING THROMBOPOIETIN RECEPTOR AGONISM | SHIONOGI & CO., LTD. | 2009-12-24 | — | — | US | disclosed |
| US-7601746-B2 | Compounds exhibiting thrombopoietin receptor agonism | SHIONOGI & CO., LTD. (JP) | 2009-10-13 | — | — | US | disclosed |
| US-20070043087-A1 | Such as 3-{2,6-difluoro-4-[4,5-dihydro-6-(3,3-dimethylbutyl)naphtho[1,2-d]thiazol-2-ylcabamoyl)phenyl]-2-methylacrylic acid | EDDINGPHARM (HONG KONG) COMPANY LIMITED (CN) | 2007-02-22 | — | — | US | disclosed |
| EP-1655291-A1 | COMPOUNDS HAVING THROMBOPOIETIN RECEPTOR AGONISM | SHIONOGI & CO., LTD. (JP) | 2006-05-10 | — | — | EP | disclosed |
| CN-1228326-C | Process for preparing N-alkenyl amides | BASF AG (DE) | 2005-11-23 | — | — | CN | disclosed |
| EP-1240139-B1 | METHOD FOR PRODUCING N-ALKENYL AMIDES | BASF AG (DE) | 2005-11-09 | — | — | EP | disclosed |
| CN-1444552-A | Method for producing alkenyl ethers | BASF AG (DE) | 2003-09-24 | — | — | CN | disclosed |
| US-6624303-B2 | By reacting the corresponding NH-amides with acetylenes in the liquid phase using a basic alkali metal compound as catalyst and as cocatalyst (di- or tri-)1,4-butanediol mono- and diethers; N-vinyl-2-pyrrolidone from pyrrolidone | BASF AKTIENGESELLSCHAFT (DE) | 2003-09-23 | — | — | US | disclosed |
| EP-1268380-B1 | METHOD FOR PRODUCING ALKENYL ETHERS | BASF AG (DE) | 2003-09-17 | — | — | EP | disclosed |
| US-20030114715-A1 | Method for producing alkenyl ethers | BOETTCHER ARND (DE) | 2003-06-19 | — | — | US | disclosed |
| CN-1411443-A | Method for producing N-alkenyl amides | BASF AG (DE) | 2003-04-16 | — | — | CN | disclosed |
| US-20030028035-A1 | Method for producing n-alkenyl amides | BASF AKTIENGESELLSCHAFT (DE) | 2003-02-06 | — | — | US | disclosed |
| EP-1240139-A1 | METHOD FOR PRODUCING N-ALKENYL AMIDES | BASF AKTIENGESELLSCHAFT (DE) | 2002-09-18 | — | — | EP | disclosed |
| WO-2001046139-A1 | METHOD FOR PRODUCING N-ALKENYL AMIDES | BASF AKTIENGESELLSCHAFT (DE) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160214972-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ESRRA, MDM2 | HTT 1774/4885MEN1 3050/4885THRB 767/4885 |
| US-20230331681-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | HTT 2521/4885MEN1 1674/4885THRB 654/4885 |
| US-20180072711-A1 | INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ESR1, GPER1, ESR2 | HTT 2699/4885MEN1 3530/4885THRB 365/4885 |
| US-20170327469-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, MDM2, ESRRA | HTT 1845/4885MEN1 2815/4885THRB 639/4885 |
| US-20090318513-A1 | COMPOUNDS EXHIBITING THROMBOPOIETIN RECEPTOR AGONISM | MPL, TEK, GHRHR | HTT 1255/4885MEN1 534/4885THRB 92/4885 |
| US-20070043087-A1 | Such as 3-{2,6-difluoro-4-[4,5-dihydro-6-(3,3-dimethylbutyl)naphtho[1,2-d]thiazol-2-ylcabamoyl)phenyl]-2-methylacrylic acid | DHFR, NAT1, ACR | HTT 1183/4885MEN1 245/4885THRB 2080/4885 |
| US-20030028035-A1 | Method for producing n-alkenyl amides | NAT1, H1-2, H1-0 | HTT 1544/4885MEN1 1890/4885THRB 2244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.